Albumin fusion protein

Abstract

Albumin fusion technology can improve the blood retention properties of protein-based pharmaceutics that have a short circulation half-life. The procedure consists of fusing the HSA gene with the gene for a therapeutic protein or peptide, thus permitting the existing recombinant protein therapeutics to be reengineered using albumin as a suitable and safe carrier. Improving the pharmacokinetic properties of biopharmaceutics by albumin fusion technology could lead to greatly extending the pharmacological activity of such pharmaceutics over a much long period of time and would permit a bolus intravenous administration with less dosing frequency, making the treatment more convenient and cost-effective. Albumin fusion technology also has benefits including improving the stability, versatility, safety, and ease of manufacture for various biopharmaceutics. Moreover, recent studies have extended the boundaries of albumin fusion technology in which a fusion protein is delivered to targeted organs and cells or to permit the efficient intracellular delivery of partner biopharmaceutics.